Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 706321 + Ustekinumab in Crohn's Disease
NCT04978493Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2021
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BI 706321 + Ustekinumab with Placebo + Ustekinumab (2 arms). Primary endpoint: Absolute Change From Baseline in Simple Endoscopic Score for Crohn's Disease at 12 weeks. Started Dec 2021; status: terminated.
02
Drugs
bi 706321
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04978493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978493.